These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
710 related articles for article (PubMed ID: 11593322)
1. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322 [TBL] [Abstract][Full Text] [Related]
2. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289 [TBL] [Abstract][Full Text] [Related]
3. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050 [TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment. Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338 [TBL] [Abstract][Full Text] [Related]
5. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310 [TBL] [Abstract][Full Text] [Related]
6. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis. Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929 [TBL] [Abstract][Full Text] [Related]
7. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674 [TBL] [Abstract][Full Text] [Related]
8. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review. Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578 [TBL] [Abstract][Full Text] [Related]
9. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302 [TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
11. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263 [TBL] [Abstract][Full Text] [Related]
12. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297 [TBL] [Abstract][Full Text] [Related]
13. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors. Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851 [TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819 [TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Yanada M; Yamamoto K; Emi N; Naoe T; Suzuki R; Taji H; Iida H; Shimokawa T; Kohno A; Mizuta S; Maruyama F; Wakita A; Kitaori K; Yano K; Hamaguchi M; Hamajima N; Morishima Y; Kodera Y; Sao H; Morishita Y Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425 [TBL] [Abstract][Full Text] [Related]
16. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717 [TBL] [Abstract][Full Text] [Related]
17. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628 [TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Vlieger AM; Boland GJ; Jiwa NM; de Weger RA; Willemze R; de Gast GC; Falkenburg JH Bone Marrow Transplant; 1992 Apr; 9(4):247-53. PubMed ID: 1318141 [TBL] [Abstract][Full Text] [Related]